Common Contracts
489 similar Sales Agreement contracts by Applied Digital Corp., AEON Biopharma, Inc., Apollomics Inc., others
Disc Medicine, Inc. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • November 15th, 2024 • Disc Medicine, Inc. • Pharmaceutical preparations • New York
Disc Medicine, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
PIXELWORKS, INC. Common Stock (par value $0.001 per share) Sales AgreementSales Agreement • November 14th, 2024 • Pixelworks, Inc • Semiconductors & related devices • New York
Pixelworks, Inc., an Oregon corporation (the “Company”), confirms its agreement (this “Agreement”) with Roth Capital Partners, LLC (the “Agent”), as follows:
UNICYCIVE THERAPEUTICS, INC. Shares of Common Stock ($0.001 par value per share) SALES AGREEMENTSales Agreement • November 13th, 2024 • Unicycive Therapeutics, Inc. • Pharmaceutical preparations • New York
Unicycive Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Guggenheim Securities, LLC (the “Agent”), as follows:
POLYPID LTD. Ordinary Shares Sales AgreementSales Agreement • November 8th, 2024 • PolyPid Ltd. • Surgical & medical instruments & apparatus • New York
POLYPID LTD., a company organized under the laws of the State of Israel (the “Company”), confirms its agreement (this “Agreement”) with Oppenheimer & Co. Inc. (the “Agent”), as follows:
Tourmaline Bio, Inc. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENTSales Agreement • November 7th, 2024 • Tourmaline Bio, Inc. • Biological products, (no disgnostic substances) • New York
Tourmaline Bio, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:
ASURE SOFTWARE, INC.Sales Agreement • October 31st, 2024 • Asure Software Inc • Services-computer integrated systems design • New York
Asure Software, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Roth Capital Partners, LLC (the “Agent”), as follows:
EVOLUTION PETROLEUM CORPORATION Common Stock ($0.001 par value per share) Sales AgreementSales Agreement • October 21st, 2024 • Evolution Petroleum Corp • Crude petroleum & natural gas • New York
Evolution Petroleum Corporation, a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with Roth Capital Partners, LLC (the “Lead Agent”), Northland Securities, Inc. (“Northland”) and A.G.P./Alliance Global Partners (“AGP,” and together with the Lead Agent and Northland, the “Agents” and each, an “Agent”), as follows:
Rumble, Inc. Shares of Class A Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • October 18th, 2024 • Rumble Inc. • Services-computer programming, data processing, etc. • New York
Rumble Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
BENITEC BIOPHARMA INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENTSales Agreement • October 11th, 2024 • Benitec Biopharma Inc. • Pharmaceutical preparations • New York
Benitec Biopharma Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:
IMMATICS N.V. Ordinary Shares (Nominal value €0.01 per share) SALES AGREEMENTSales Agreement • October 10th, 2024 • Immatics N.V. • Biological products, (no disgnostic substances) • New York
Immatics N.V., a public limited liability company (naamloze vennootschap) under Dutch law (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:
Neumora Therapeutics, Inc. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENTSales Agreement • October 1st, 2024 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Neumora Therapeutics, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:
PROQR THERAPEUTICS N.V. Ordinary Shares (nominal value €0.04 per share) Sales AgreementSales Agreement • September 30th, 2024 • ProQR Therapeutics N.V. • Pharmaceutical preparations • New York
ProQR Therapeutics N.V., a Dutch public company with limited liability (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
ZURA BIO LIMITED US$125,000,000 CLASS A ORDINARY SHARES SALES AGREEMENTSales Agreement • September 3rd, 2024 • Zura Bio LTD • Biological products, (no disgnostic substances) • New York
Zura Bio Limited, a Cayman Islands exempted company (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:
AEON BIOPHARMA, INC. Shares of Class A Common Stock ($0.0001 par value per share) SALES AGREEMENTSales Agreement • August 15th, 2024 • AEON Biopharma, Inc. • Pharmaceutical preparations • New York
On the date hereof, AEON Biopharma, Inc., a Delaware corporation (the “Company”), has filed or will file with the Securities and Exchange Commission (the “Commission”) a shelf registration statement on Form S-3 that contains a base prospectus as well as a sales agreement prospectus covering the offering, issuance and sale by the Company of shares of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $50,000,000. The parties agree to be legally bound by the terms of this Agreement effective immediately upon such registration statement being declared effective by the Commission.
Sagimet Biosciences Inc. Shares of Series A Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • August 15th, 2024 • Sagimet Biosciences Inc. • Pharmaceutical preparations • New York
Sagimet Biosciences Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
Perspective Therapeutics, Inc. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • August 13th, 2024 • Perspective Therapeutics, Inc. • Surgical & medical instruments & apparatus • New York
Perspective Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC (each, an “Agent” and together, the “Agents”), as follows:
Riot Platforms, Inc. Shares of Common Stock (no par value per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • August 9th, 2024 • Riot Platforms, Inc. • Finance services
Riot Platforms, Inc., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co., B. Riley Securities, Inc., BTIG, LLC, Roth Capital
PLBY GROUP, INC. Common Stock ($0.0001 par value per share) Sales AgreementSales Agreement • August 8th, 2024 • PLBY Group, Inc. • Retail-miscellaneous retail • New York
PLBY Group, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Roth Capital Partners, LLC (the “Agent”), as follows:
SONIM TECHNOLOGIES, INC. Common Stock ($0.001 par value per share) Sales AgreementSales Agreement • August 7th, 2024 • Sonim Technologies Inc • Telephone & telegraph apparatus • New York
Sonim Technologies, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Roth Capital Partners, LLC (the “Agent”), as follows:
Poseida Therapeutics, Inc. Shares of Common Stock (par value $0.0001 per share) Amended & Restated Controlled Equity OfferingSM Sales AgreementSales Agreement • August 5th, 2024 • Poseida Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Poseida Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
APPLIED DIGITAL CORPORATION Common Stock (par value $0.001 per share) Sales AgreementSales Agreement • July 9th, 2024 • Applied Digital Corp. • Services-computer processing & data preparation • New York
Mind Medicine (MindMed) Inc. Common Shares (no par value per share) Sales AgreementSales Agreement • June 28th, 2024 • Mind Medicine (MindMed) Inc. • Medicinal chemicals & botanical products • New York
Mind Medicine (MindMed) Inc., a corporation incorporated under the laws of the Province of British Columbia (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:
InflaRx N.V. Ordinary Shares (nominal value €0.12 per share) SALES AGREEMENTSales Agreement • June 28th, 2024 • InflaRx N.V. • Pharmaceutical preparations • New York
InflaRx N.V., a public limited liability company (naamloze vennootschap) under Dutch law (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:
Keros Therapeutics, Inc. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENTSales Agreement • June 17th, 2024 • Keros Therapeutics, Inc. • Pharmaceutical preparations • New York
Keros Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Leerink LLC (the “Agent”), as follows:
Semler Scientific, Inc. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • June 6th, 2024 • Semler Scientific, Inc. • Electromedical & electrotherapeutic apparatus • New York
Semler Scientific, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
HYZON MOTORS INC. Class A Common Stock ($0.0001 par value per share) Sales AgreementSales Agreement • June 6th, 2024 • Hyzon Motors Inc. • Electrical industrial apparatus • New York
Hyzon Motors Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Roth Capital Partners, LLC (“Roth”) and BTIG, LLC (“BTIG”; each of Roth and BTIG, an “Agent” and together, the “Agents”), as follows:
APOLLOMICS INC. Class A Ordinary Shares (par value $0.0001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • May 24th, 2024 • Apollomics Inc. • Pharmaceutical preparations • New York
Apollomics Inc., a Cayman Islands exempted company (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
Sales AgreementSales Agreement • May 24th, 2024 • Kingstone Companies, Inc. • Fire, marine & casualty insurance • New York
Kingstone Companies, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Janney Montgomery Scott LLC (“Janney” or the “Agent”), as follows:
ContractSales Agreement • May 10th, 2024 • BigBear.ai Holdings, Inc. • Services-prepackaged software
CORMEDIX INC. Common Stock (par value $0.001 per share) SALES AGREEMENTSales Agreement • May 9th, 2024 • CorMedix Inc. • Pharmaceutical preparations • New York
CorMedix Inc., a Delaware corporation (the “Company”) and Leerink Partners LLC (the “Agent”, together with the Company, each a “Party” and collectively, the “Parties”) and hereby agree as follows:
Oculis Holding AG Ordinary Shares (CHF 0.01 nominal value per share) SALES AGREEMENTSales Agreement • May 8th, 2024 • Oculis Holding AG • Pharmaceutical preparations • New York
Oculis Holding AG, a stock corporation (Aktiengesellschaft) incorporated and existing under the laws of Switzerland (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:
APPLIED DIGITAL CORPORATION Common Stock (par value $0.001 per share)Sales Agreement • May 6th, 2024 • Applied Digital Corp. • Services-computer processing & data preparation • New York
Applied Digital Corporation, a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with Roth Capital Partners, LLC (the “Agent”) as follows:
Codexis, Inc. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • May 2nd, 2024 • Codexis, Inc. • Industrial organic chemicals • New York
Codexis, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
Intuitive Machines, Inc. Shares of Class A Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • April 5th, 2024 • Intuitive Machines, Inc. • Search, detection, navagation, guidance, aeronautical sys • New York
Intuitive Machines, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
VINCERX PHARMA, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENTSales Agreement • March 29th, 2024 • Vincerx Pharma, Inc. • Pharmaceutical preparations • New York
Vincerx Pharma, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:
